Table 1.

Ongoing phase I trials with moxetumomab pasudotox

DiseasesPrior therapy needed for eligibilityCurrent location
HCL≥2 prior therapies, ≥2 purine analogue courses, unless response to first course was <2 yearsNIH
CLLa≥2 prior therapies, ≥1 with rituximabNIH, SCRI, IU, MUSC, CCCN, CSMC
DLBCL, MCL≥1 prior therapy with rituximab
FL≥2 prior therapies, ≥1 with rituximab
ALL (pediatric)≥2 prior therapies, prior HSCT allowedNIH, SJ, DF

Abbreviations: CCCN, Comprehensive Cancer Center of Nevada; CSMC, Cedars Sinai Medical Center; DF, Dana-Farber Cancer Institute; DLBCL, diffuse large B-cell lymphoma; HSCT, hematopoietic stem cell transplant; IU, Indiana University; MCL, mantle cell lymphoma; MUSC, Medical University of South Carolina; SCRI, Sarah Cannon Research Institute; SJ, Saint Jude Children's Research Hospital.

  • aListed as a phase I–II trial.